Strata Critical Medical, Inc.

Strata Critical Medical, Inc. Earnings Recaps

SRTA 3 recaps
Next earnings: March 2, 2027 (estimated) · full calendar
Q3 2026 Nov 5, 2026

Shares rose 3.7% after earnings, as Strata reported Q3 results ahead of its guidance and record free cash flow. Clinical services growth and earlier-than-planned logistics margin progress supported management’s outlook for 2027.

Key takeaways
  • Clinical services revenue grew more than 20% sequentially from Q2 2026, which management attributed partly to customers using Strata’s integrated transplant offering for more cases.
  • Logistics revenue was near the high end of guidance despite a larger-than-expected seasonal industry decline and shorter industry trip distances.
  • Strata said it reached its 2027 logistics gross margin target ahead of plan and reduced adjusted SG&A quarter over quarter.
  • Free cash flow reached a record $8.6 million; the company ended the quarter with roughly $42 million in cash and short-term investments, before an anticipated $27 million in passenger-sale consideration early next year.
  • Management said it expects high-teens organic adjusted EBITDA growth and 30%+ total adjusted EBITDA growth in 2027, including acquisitions; it also announced a $20 million share repurchase authorization.
Q2 2026 Aug 6, 2026

The stock gained 5.4% after reporting better-than-expected growth in the clinical business, driven by strong 23.8% sequential growth in Transplant Clinical revenue and expanding gross margins, which outweighed softness in the Logistics segment.

Key takeaways
  • Clinical revenue increased 15.1% sequentially on an organic basis, fueled by 23.8% growth in Transplant Clinical services.
  • Clinical gross margins improved to 26.1% in Q2 from 25% in Q1, enhancing overall profitability.
  • Logistics revenue faced headwinds due to significantly reduced flying volumes with one nonexclusive customer, impacting about 3% of segment revenue; volume reduction expected to impact full Q3 before recovery.
  • Operating cash flow was $5.7 million with free cash flow of $2.9 million, marking the second consecutive quarter of positive cash generation.
  • Closed three bolt-on acquisitions expanding clinical capabilities and geographic reach, strengthening future growth and margin profile while advancing capital deployment ahead of plan.
Q1 2026 May 7, 2026

Strata’s shares rallied 10.8% following a quarter marked by robust revenue growth driven by Logistics and new Clinical business lines, alongside positive signs of improving cash flow and an active M&A pipeline that exceeded investor expectations.

Key takeaways
  • Reported 87% year-over-year revenue growth, led by 32% organic growth in Logistics and strong contributions from the new Clinical segment.
  • Generated operating and free cash flow before aircraft acquisitions for the first time this quarter, indicating improved earnings quality.
  • Announced a new acquisition of Ohio Valley Perfusion Associates, aligned with a broader M&A strategy targeting fragmented markets with mid-single-digit EBITDA multiples.
  • Expanded logistics footprint with a new base in Chicago and a total fleet of 10 owned aircraft plus 35 dedicated, enhancing national service coverage.
  • Industry trends toward increased adoption of NRP and third-party surgical recovery have offset declines in donor volume, supporting demand for Strata’s integrated platform.